Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.20 [0.02; 1.72]
0.20 [0.02 ; 1.72 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable symptomatic Covid-19detailed results AstraZeneca phase 3 US (D8110C00001), 2021 0.24 [0.18; 0.32]
ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.26; 0.43]
0.29 [0.21 ; 0.39 ] AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020 2 65% 17,177 low not evaluable asymptomatic COVID casedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.23; 0.48]
0.33 [0.23 ; 0.48 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable infection (PCR positive symptomatic or not)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.44 [0.33; 0.59]
0.44 [0.33 ; 0.59 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 11,636 NA not evaluable severe COVID-19 occurrencedetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54]
0.49 [0.02 ; 14.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.24 [0.14; 0.41]
0.24 [0.14 ; 0.41 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 18,494 NA not evaluable serious adverse eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.86 [0.64; 1.17]
0.86 [0.64 ; 1.17 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable adverse eventsdetailed results Asano, 2022 1.44 [0.71; 2.93]
AstraZeneca phase 3 US (D8110C00001), 2021 1.62 [1.54; 1.71]
1.62 [1.54 ; 1.70 ] Asano, 2022, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 32,635 NA not evaluable ATE (Myocardial infarction or ischemic stroke)detailed results AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.44 [0.15; 1.27]
AstraZeneca phase 3 US (D8110C00001), 2021 0.12 [0.01; 2.77]
0.39 [0.14 ; 1.06 ] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021 2 0% 56,623 NA not evaluable Guillain-Barré syndrome detailed results AstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81]
1.00 [0.03 ; 29.81 ] AstraZeneca phase 3 US (D8110C00001), 2021 1 0% 32,379 NA not evaluable intracranial hemorrhage detailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.01; 5.40]
AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21]
0.32 [0.04 ; 2.56 ] Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021 3 0% 56,879 NA not evaluable ischemic strokedetailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.32 [0.03; 3.12]
AstraZeneca phase 3 US (D8110C00001), 2021 0.13 [0.01; 2.77]
0.25 [0.05 ; 1.30 ] Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021 3 0% 56,879 NA not evaluable Myocardial infarction detailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.03; 2.18]
AstraZeneca phase 3 US (D8110C00001), 2021 0.25 [0.01; 7.46]
0.26 [0.05 ; 1.37 ] Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021 3 0% 56,879 NA not evaluable pulmonary embolismdetailed results Asano, 2022 0.33 [0.01; 16.88]
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.49 [0.02; 14.52]
AstraZeneca phase 3 US (D8110C00001), 2021 0.50 [0.01; 25.21]
0.44 [0.05 ; 3.75 ] Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021 3 0% 56,879 NA not evaluable serious adverse events (SAE), anydetailed results Asano, 2022 0.16 [0.01; 4.96]
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.83 [0.64; 1.07]
AstraZeneca phase 3 US (D8110C00001), 2021 0.95 [0.68; 1.33]
0.87 [0.71 ; 1.06 ] Asano, 2022, AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020, AstraZeneca phase 3 US (D8110C00001), 2021 3 0% 56,879 NA not evaluable venous thromboembolism detailed results AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 0.24 [0.01; 5.40]
0.24 [0.01 ; 5.40 ] AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 1 0% 24,244 NA not evaluable Bell's palsydetailed results AstraZeneca phase 3 US (D8110C00001), 2021 1.00 [0.03; 29.81]
ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.20; 4.83]
0.98 [0.23 ; 4.17 ] AstraZeneca phase 3 US (D8110C00001), 2021, ChAdOx1 phase 3 (AstraZeneca), 2020 2 0% 56,124 moderate not evaluable immediate allergic reactiondetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15]
1.95 [0.07 ; 58.15 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable multiple sclerosisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.07; 58.15]
1.95 [0.07 ; 58.15 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable myelitisdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.95 [0.18; 21.52]
1.95 [0.18 ; 21.52 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Gastrointestinal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.33 [0.03; 3.13]
0.33 [0.03 ; 3.13 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Musculoskeletal disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.98 [0.06; 15.60]
0.98 [0.06 ; 15.60 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Neuroinflammatory disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 1.22 [0.33; 4.54]
1.22 [0.33 ; 4.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Skin disordersdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.73 [0.16; 3.27]
0.73 [0.16 ; 3.27 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Potential Immune Vasculitidesdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.02; 14.54]
0.49 [0.02 ; 14.54 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable Thromboembolic eventsdetailed results ChAdOx1 phase 3 (AstraZeneca), 2020 0.49 [0.15; 1.62]
0.49 [0.15 ; 1.62 ] ChAdOx1 phase 3 (AstraZeneca), 2020 1 0% 23,745 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-19 16:52 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 89
- treatments: 759
- roots T: 290